P-21
guinea pig
The Dose Guy’s verdictSep 1, 20262 sources
An elegant piece of peptide design with a strong animal story and no human evidence at all. P-21 drives BDNF and neurogenesis in most rodent models it has been tested in, including genuinely impressive Alzheimer’s mouse data, though it fell short in a CDKL5 knockout model. But none of that has been tested in a person, and the distance from a disease-model mouse to a healthy human brain is real. If the neurogenesis angle interests you, NSI-189 at least reached human trials. P-21 is a bet on the mechanism, nothing more.
What it is
A four-amino-acid peptide carved from the most active region of ciliary neurotrophic factor, or CNTF, one of the brain’s own growth signals. The designers added an adamantane cap to help it cross the blood-brain barrier and resist degradation, so it can be taken orally in animal studies, which is unusual for a peptide this small. Once inside, it increases BDNF expression in the hippocampus, promoting new neuron growth and synaptic repair.
The research program behind P-21 is focused on Alzheimer’s prevention, not nootropic enhancement. Every published study uses a disease model: aged rats, triple-transgenic Alzheimer’s mice, or Down syndrome mice. On this shelf, NSI-189 is the neurogenesis compound that actually reached human trials. P-21 is the one still waiting for its first dose in a person.
What the research shows
All rodent, all disease models. Mostly positive, with one negative result, and zero human confirmation.
Realistic protocols
I am not building a protocol out of mouse Alzheimer’s studies. For the record, the community runs P-21 at roughly 1 to 2 mg daily, subcutaneously, in cycles of four to six weeks. The animal studies delivered it orally mixed into chow at body-weight-scaled doses that do not translate to a pill, so the community defaults to injection to bypass the absorption question. That dosing is extrapolated from the animal literature and other people’s logs, not from any pharmacokinetic study in a person. If you run it anyway: start at the low end, keep the cycle short, log what you notice, and do not pretend that positive mouse data is a safety guarantee. Growth-factor signaling in a brain that does not have Alzheimer’s is uncharted territory.
Side effects
No human has been formally studied on P-21. Everything here is community report:
